National Phd in Systems Medicine
Doctoral programme (PhD)
A.Y. 2025/2026
Study area
Medicine and Healthcare
PhD Coordinator
The national doctoral program in Systems Medicine involves the participation of seven universities (UNIMI as the administrative site, Humanitas University, UNIBA, UNICatt, UNINA, UNITN, UNITO) and eight research centers. It is based on three main characteristics: competitive selection, intensive tutoring, and advanced training. The organizational model includes the effective sharing of educational and research activities among the different institutions involved, as well as exchange and mobility of professors and doctoral students, and forms of co-supervision.
Advances in genetics and genomic sciences have triggered a revolution, transforming classical Medicine into what is now known as Precision Medicine. This new approach is based on the acquisition and integration of vast amounts of quantitative molecular data and their use for a personalized definition of disease and targeted therapy. The transition to Precision Medicine requires professionals with new skills and multidisciplinary training.
The national doctoral program in Systems Medicine aims to provide doctors and scientists with interdisciplinary theoretical and technological training in biomedical sciences to address the challenges of precision medicine. The goal is to train professionals capable of tackling highly complex technological and therapeutic strategies with multidisciplinary approaches, enabling them to: i) manage emerging areas of medicine (e.g., quantitative biology, biomarkers, personalized medicine, etc.); ii) conduct research in multidisciplinary teams focused on solving biomedical problems; and iii) analyze the economic, ethical, and/or psychosocial issues associated with research and/or disease management.
The doctoral program is organized into Research Areas proposed by the participating institutions based on their characteristics and areas of scientific excellence, such as: Cancer Biology, Computational Biology, Genomic Medicine, Immunology, Medical Humanities, Molecular and Cellular Biology, Molecular Therapy, Neurobiology, Structural Biology. These areas intersect and serve as the foundation for a broad, interdisciplinary, and multidisciplinary doctoral program that can easily incorporate other areas of expertise.
Advances in genetics and genomic sciences have triggered a revolution, transforming classical Medicine into what is now known as Precision Medicine. This new approach is based on the acquisition and integration of vast amounts of quantitative molecular data and their use for a personalized definition of disease and targeted therapy. The transition to Precision Medicine requires professionals with new skills and multidisciplinary training.
The national doctoral program in Systems Medicine aims to provide doctors and scientists with interdisciplinary theoretical and technological training in biomedical sciences to address the challenges of precision medicine. The goal is to train professionals capable of tackling highly complex technological and therapeutic strategies with multidisciplinary approaches, enabling them to: i) manage emerging areas of medicine (e.g., quantitative biology, biomarkers, personalized medicine, etc.); ii) conduct research in multidisciplinary teams focused on solving biomedical problems; and iii) analyze the economic, ethical, and/or psychosocial issues associated with research and/or disease management.
The doctoral program is organized into Research Areas proposed by the participating institutions based on their characteristics and areas of scientific excellence, such as: Cancer Biology, Computational Biology, Genomic Medicine, Immunology, Medical Humanities, Molecular and Cellular Biology, Molecular Therapy, Neurobiology, Structural Biology. These areas intersect and serve as the foundation for a broad, interdisciplinary, and multidisciplinary doctoral program that can easily incorporate other areas of expertise.
Tutte le classi di laurea magistrale - All classes master's degree
Dipartimento di Scienze della Salute - Via di Rudinì 8 - Milano (MI)
- Main offices
Dipartimento di Scienze della Salute- Via di Rudinì 8 - Milano (MI) - Degree course coordinator: Pasini Diego
Via Adamello, 16 - IFOM - Istituto FIRC di Oncologia Molecolare ed. 9
[email protected] - Degree course website
https://www.semm.it/education/phd-program-systems-medicine
| Title | Professor(s) |
|---|---|
| Unveiling the dark proteome of cancer: Defining the Existence and Therapeutic Potential of Noncanonical ORFs in Cancer |
A. Bachi (IFOM)
|
| Functional proteomics |
A. Bachi (IFOM)
|
| Modulating DNA Repair Pathways to Enhance Immune Responsiveness in Colorectal Cancer |
A. Bardelli UNITO
|
| Genomics of Cancer and Targeted Therapies |
A. Bardelli UNITO
|
| Multi-omics characterization of the cellular adaptation to suistained hypoxia |
F. Buffa (IFOM)
|
| Artificial intelligence & System Biology |
F. Buffa (IFOM)
|
| Subcellular heterogeneity of the ribosomal machinery from structure to function |
L. Calviello (HT)
|
| Deciphering the role of lncRNA in regulating genome activity |
P. Carninci (HT)
|
| Molecular mechanism of RNA modifying machines |
A. Casañal (HT)
|
| Molecular Mechanisms of RNA Editing Macromolecular Complexes |
A. Casañal (HT)
|
| When protection from autoimmunity causes aggressive B cell lymphomas: from molecular mechanisms to clinical implications |
S. Casola (IFOM)
|
| Mastering the Survival Secrets of Cancer: Unveiling and Targeting the Hidden Mechanisms Behind Cancer Therapy Resistance and Cellular Endurance | |
| Synthetic Lethality Approaches to selectively kill BRCA1 and BRCA2 Deficient Tumors by targeting DNA replication gaps | |
| The role of DNA damage-induced non coding RNA in cancer and aging |
F. d'Adda di Fagagna (IFOM)
|
| Targeting ALT-positive tumors with antisense oligonucleotides: telomere biology, mechanisms, and resistance |
F. d'Adda di Fagagna (IFOM)
|
| Telomere dynamics in aging and cancer: exploring therapeutic potential beyond cancer cells |
F. d'Adda di Fagagna (IFOM)
|
| Impact of telomere dysfunction on immune system deregulation |
F. d'Adda di Fagagna (IFOM)
|
| Investigating telomere loss during replication |
Y. Doksani (IFOM)
|
| Unraveling the Mechanisms of eccDNA Formation |
Y. Doksani (IFOM)
|
| Organization of Neuronal Nucleoli In Situ |
P. Erdmann (HT)
|
| Understanding Biomolecular Condensation in Neurodegenerative Disease Models from In Vitro to Tissue |
P. Erdmann (HT)
|
| A High-Resolution Approach to Reconstituting Excitatory Synapses |
P. Erdmann (HT)
|
| Novel senolytic targets for the treatment of age-associated diseases |
M. Kovatcheva (IFOM)
|
| Cell plasticity and aging |
M. Kovatcheva (IFOM)
|
| Investigating the developmental origins of cancer |
M. Kovatcheva (IFOM)
|
| Maladaptive cell plasticity in the progression from tissue injury to tumorigenesis |
M. Kovatcheva (IFOM)
|
| Uncovering DDR Factors that influence tumor immunogenicity |
G. Leuzzi (IFOM)
|
| Defining the impact of Single Nucleotide Variants (SNVs) on cancer immunity |
G. Leuzzi (IFOM)
|
| Molecular and functional analysis of pancreatic cancer heterogeneity |
G. Natoli (IEO)
|
| Transcriptional Control in Inflammation and Cancer |
G. Natoli (IEO)
|
| Mechanisms and functional implications of control of extragenic transcription |
G. Natoli (IEO)
|
| Molecular bases and functional implications of cellular heterogeneity in pancreatic cancer |
G. Natoli (IEO)
|
| The modulatory role of the gut microbiome on the balance between antigen-specific and bystander immune responses in solid tumors |
L. Nezi (IEO)
|
| Non-genetic mechanisms of drug-resistance in Acute Myeloid Leukemia (AML). | |
| Breast-cancer cell-phenotypes selected during metastatization and treatment. | |
| Functional and genetic characterization of Enhancer-promoter networks in breast cancer. | |
| Structural and Functional Characterization of Primary Cilia Diversity in Health and Disease |
G. Pigino (HT)
|
| Cancer Epigenetics |
P. Scaffidi (IEO)
|
| Epigenetic mechanisms in health and cancer |
P. Scaffidi (IEO)
|
| The hidden drivers of cancer |
M. Schaefer (IEO)
|
| The cancer code: unraveling selection across the cancer genome and epigenome |
M. Schaefer (IEO)
|
| Microbiome signatures of early on-set colorectal cancer risk factors |
N. Segata (UNITN)
|
| Microbiome signatures of early on-set colorectal cancer |
N. Segata (UNITN)
|
| High-resolution computational metagenomics for the study of the transmission of the human microbiome |
N. Segata (UNITN)
|
| Metagenomics, microbiome, bacterial infection |
N. Segata (UNITN)
|
| Investigating molecular and cellular determinants of B cell differentiation |
B. Soskic (HT)
|
| Dissecting gene-environment interactions in human brain development and neurodevelopmental disorders through brain organoid and single cell multi-omic modelling |
G. Testa
|
| Stem Cell and Organoid Epigenetics |
G. Testa
|
| Dissecting gene-environment interactions in human brain development through single cell resolution analysis and mathematical modelling |
G. Testa
|
| Dissecting gene-environmental interactions in human brain development through advanced organoid modelling |
G. Testa
|
| Genome editing in liver for therapy of inherited diseases |
A. Auricchio
|
| Genome editing in retina for therapy of inherited diseases |
A. Auricchio
|
| Novel AAV serotypes for efficient gene delivery in vivo |
A. Auricchio
|
| Engineering Synthetic Gene Circuits for advancing gene and cell therapy |
D. di Bernardo
|
| Investigation of intertwined relationships between healthy and mutated GLUT1 using FDA approved compounds to identify a therapeutic approach. |
P. Grumati
|
| Deciphering Variants of Unknown Significance (VUS) Through High-Throughput Functional Genomics |
D. Cacchiarelli
|
| Targeting mitochondrial turnover as a therapeutic strategy in rare and common neurodegenerative diseases. |
A. Indrieri
|
| Pharmacological activation of lysosomal hydrolases trafficking to reduce Lysosomal Storage |
D. Medina
|
| Dissecting and piloting the intracellullar tarfficking of AAVs. / |
MA. De Matteis
|
| Pharmacological approaches to correct the basic defect in cystic fibrosis. |
L.J.V. Galietta
|
| New therapies for inherited metabolic disorders\ |
N. Brunetti Pierri
|
| RNA aptamers inhibiting mutant Z α1-antitrypsin polymerization |
P. Piccolo
|
| AAV-based genome editing for liver inherited diseases with liver fibrosis |
P. Piccolo
|
| Targeting inflammation as therapeutic approach for Alpha1 Antitrypsin liver disease/ |
N. Pastore
|
| Regulation of Lysosomal Exocytosis in Health and Disease- |
C. Di Malta
|
| Lysosomal Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)- |
C. Di Malta
|
| TFEB Regulation by the Vacuolar ATPase and Its Relevance to Birt-Hogg-Dubé (BHD) Syndrome |
C. Di Malta
|
| Unraveling AAV trafficking in animal models of Inherited Retinal Disorders |
M. Cortese
|
| Lysosomal signaling in metabolic diseases |
G. Napolitano
|
| Innovative gene therapy and genome editing approaches for treatment of inherited disorders |
I. Trapani
|
| Development of AAV-based therapies for inherited kidney diseases |
L. Staiano
|
| Advancing Gene Therapy: On/Off-Target Identification Using Third-Generation Sequencing |
G. Gambardella
|
| The OFD1 puzzle: one gene several diseases |
B. Franco
|
| Study of the primary molecular events leading to cystogenesis |
B. Franco
|
| The primary cilium as a therapeutic target in bile duct cancer |
B. Franco
|
| miR-181a/b down regulation as a therapeutic approach for Leigh syndrome |
B. Franco
|
| Towards dissecting the clinical variability observed in HNF‑1β associated phenotypes |
B. Franco
|
| Biochemical and biophisical approaches to study receptor endocitosis and endosomal membrane fusion |
M.Zerial
|
Enrolment
Call for applications
Please refer to the call for admission test dates and contents, and how to register.
Application for admission: please refer to the call
Following the programme of study
Contacts
Office and services for PhD students and companies